FUNDING
Company Profile
Clinical-stage biotech developing deupirfenidone, a deuterated pirfenidone-derived drug for idiopathic pulmonary fibrosis, spun out of PureTech Health.
Founded 2025Boston, MA$180M raised
Investors
RA Capital ManagementLeaps by BayerPureTech Health
Compare with
Funding & Valuation History
from our coverage| Date | Event | Amount | Valuation | Source |
|---|---|---|---|---|
| Jul 2, 2026 | Celea Therapeutics Raises $180M Series B for Pulmonary Fibrosis Drug | $180M Series B | — | Story → |
Celea Therapeutics FAQ
- How much has Celea Therapeutics raised?
- Celea Therapeutics has raised approximately $180M in total funding to date.
- Is Celea Therapeutics publicly traded?
- No. Celea Therapeutics is privately held.
- Who are Celea Therapeutics's investors?
- Celea Therapeutics's investors include RA Capital Management, Leaps by Bayer, PureTech Health.
Coverage Timeline
newest first- Jul 5, 2026FUNDINGBiotech VCs Are Betting Big on Single Clinical Trials$391M+ combined across 3 single-trial bets→
- Jul 4, 2026FUNDINGThe Return of the $100M+ Vertical AI Round$100M-$180M vertical AI rounds→
- Jul 2, 2026FUNDINGCelea Therapeutics Raises $180M Series B for Pulmonary Fibrosis Drug$180M Series B→
- Jul 2, 2026FUNDINGCelea Therapeutics Raises $180M to Push Lung Drug Into Phase 3$180 million→
All Coverage
FUNDING$391M+ combined across 3 single-trial bets
Biotech VCs Are Betting Big on Single Clinical Trials
Celea Therapeutics' $180M round, Beeline Medicine's $126.3M raise and Flare Therapeutics' $85M financing show late-stage biotech investors concentrating capital into single, high-conviction trial bets rather than diversified platform plays.
FUNDING
The Return of the $100M+ Vertical AI Round
FUNDING$100M-$180M vertical AI rounds
The Return of the $100M+ Vertical AI Round
TwelveLabs' $100M video-AI raise and Celea Therapeutics' $180M biotech round show growth-stage investors writing nine-figure checks into narrow, vertical AI applications again, not just horizontal infrastructure plays.
FUNDING
Celea Therapeutics Raises $180M Series B for Pulmonary Fibrosis Drug
FUNDING$180M Series B
Celea Therapeutics Raises $180M Series B for Pulmonary Fibrosis Drug
Celea Therapeutics, a clinical-stage biotech spun out of PureTech developing deupirfenidone for idiopathic pulmonary fibrosis, announced a $180 million Series B on July 2, led by RA Capital and Leaps by Bayer, with PureTech and additional unnamed.
FUNDING
Celea Therapeutics Raises $180M to Push Lung Drug Into Phase 3
FUNDING$180 million
Celea Therapeutics Raises $180M to Push Lung Drug Into Phase 3
PureTech-founded Celea Therapeutics raised $180 million to fund a head-to-head Phase 3 trial testing its drug deupirfenidone against the current standard of care for idiopathic pulmonary fibrosis.